As investors and industry observers track the launch of Casgevy (exagamglogene autotemcel) and Lyfgenia (lovotibeglogene autotemcel), gene-based therapies approved in December 2023 for certain sickle cell disease and beta thalassemia patients, the CEOs of CRISPR Therapeutics AG and bluebird bio are exuding confidence that all will go well commercially.
“I don’t see fundamental roadblocks or fundamental issues as we look at these launches,” Samarth Kulkarni, CEO of CRISPR
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?